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Abstract 
Follicle stimulating hormone (FSH) acts through the Sertoli cell to ensure normal testicular 
development and function. To  identify transcriptional  mechanisms through which FSH acts in 
the testis we have treated gonadotrophin-deficient hypogonadal (hpg) mice with recombinant FSH 
and  measured changes in testicular transcript levels using microarrays and real-time PCR 12, 24 5 
and 72h after the start of treatment. Approximately 400 transcripts were significantly altered at 
each time point by FSH treatment. At 12h there was a clear increase in the levels of a number of  
transcripts known to be expressed in the Sertoli cells (eg Fabp5, Lgals1, Tesc, Scara5, Aqp5). 
Additionally, level of  Leydig cell transcipts were also markedly increased (eg Ren1, Cyp17a1, 
Akr1b7, Star, Nr4a1). This was associated with a small but significant rise in testosterone at 24 10 
and 72h. At 24h, androgen-dependent Sertoli cell transcripts were upregulated  (eg Rhox5, Drd4, 
Spinlw1, Tubb3 and Tsx) and this trend continued up to 72h. Surprisingly, only 4 germ cell 
trancripts (Dkkl1, Hdc, Oct4 and 1700021K02Rik) were altered by FSH within the time-course of 
the experiment. Pathway analysis showed changes in cell cycle and cell proliferation pathways at 
all times and a  general decline in transcripts related to formation and regulation of tight junctions. 15 
Results show FSH acts directly and indirectly to induce rapid changes in Sertoli cell and Leydig 
cell transcript levels in the hpg mouse but that effects on germ cell development must occur over a 
longer time span.  
 
 3 
Introduction 
 
Postnatal testicular growth, spermatogenesis 
and fertility are dependent upon the pituitary 
gonadotrophins follicle-stimulating hormone 5 
(FSH) and luteinising hormone (LH). LH acts 
directly on Leydig cells to stimulate androgen 
production while androgens and FSH stimulate 
spermatogenesis through direct action on the 
Sertoli cells (1). The role of gonadotrophins is 10 
clearly seen in the hypogonadal (hpg) mouse 
which lacks gonadotrophin releasing hormone 
(GnRH) (2) and, consequently, has 
undetectable circulating levels of LH and FSH  
(3). The gonads of the hpg mouse remain in a 15 
pre-pubertal state throughout life, with 
spermatogenesis blocked at early meiosis (3;4) 
although treatment with exogenous 
gonadotrophins or androgens will increase 
testicular growth and restore germ cell 20 
development (5-8).   In recent years, generation 
of mice lacking individual hormones or 
hormone receptors has allowed us to 
investigate more clearly the roles played by 
LH, FSH and androgen in regulation of 25 
testicular function. In particular, study of mice 
lacking androgen receptors (AR) in the Sertoli 
cells (SCARKO (9)) have shown that 
androgens are essential for spermatocyte 
progression through meiosis. In contrast, mice 30 
lacking FSH (FSHβKO (10)) or the FSH-
receptor (FSHRKO) (11;12) are fertile with all 
stages of spermatogenesis present. 
Nevertheless, in FSHRKO and FSHβKO mice 
there is a reduction in sperm number and 35 
quality (13;14) suggesting that FSH may act to 
optimise spermatogenesis. In addition, 
comparison of SCARKO mice with mice 
lacking both FSHR and AR on the Sertoli cells 
has shown that  FSH acts to increase Sertoli 40 
cell number, total germ cell number and the 
number of germ cells associated with each 
Sertoli cell (15). This is achieved by an  
increase in  the number of spermatogonia and 
enhanced  entry of these cells into meiosis (15).45 
  
Previous studies have identified a 
number of Sertoli cell products or mRNA 
transcripts that are FSH-sensitive including, for 
example, inhibin, AR, transferrin, DMRT, 50 
androgen binding protein and CREM  (16-20). 
In addition, a previous study Sadate-Ngatchou 
et al (21)   has examined the short term effects 
of FSH on testicular gene expression in vivo 
using arrays.  In this series of experiments 55 
adult hpg mice were given a single injection of 
FSH and transcript levels  were shown to peak 
4h after injection and diminish thereafter (21).  
This study shows the acute response of the 
testis to FSH stimulation but we continue to   60 
lack a clear understanding of how FSH acts to 
regulate testicular development and function 
over the longer term. To extend and 
complement the earlier work of  Sadate-
Ngatchou et al (21), therefore,   we have 65 
carried  out a more comprehensive review  of 
the effects of FSH on transcript levels in the 
testis of the hpg mouse.  
 
 70 
Materials and Methods 
 
Animals and treatments 
hpg mice from the original colony first 
identified at the MRC Laboratories, Harwell, 75 
Oxford (3) were bred at Oxford. The hpg 
mutation was identified by PCR analysis of tail 
DNA as previously reported (22). All 
procedures were carried out in accordance with 
the UK Animals (Scientific Procedures) Act 80 
1986 and with the approval of a local ethical 
review committee.  
Male hpg mice, 10 weeks of age, were injected 
sub-cutaneously with 8 IU recombinant human 
FSH (Serono Ltd. Middlesex, UK) in 0.2 ml 85 
PBS (phosphate buffered saline, pH 7.4, Sigma 
Aldrich, Dorset, UK) every 12 hours for 12, 24, 
or 72 hours. This dose of recombinant hormone 
had previously been shown to induce a 
significant increase in testis weight in hpg mice 90 
when given for one week (Abel and Charlton 
unpublished). Mice were killed one hour after 
the last injection, testes removed, snap frozen 
in liquid nitrogen and stored at –70oC.   
 95 
Testicular histology 
Three hpg mice treated as above, were 
sacrificed at each timepoint.  The testes were 
weighed and one testis from each animal was 
fixed in 1% glutaraldehyde, 4% 100 
paraformaldehyde, in phosphate buffer, 0.1M, 
pH 7.2 for 24hrs at 4oC and embedded in 
araldite. Semi-thin, 1µ sections were cut and 
stained with toluidine blue.  
 105 
 
 
 
 4 
DNA Microarray 
Three or four animals from FSH-treated or 
control hpg groups were killed at  each 
timepoint and the RNA from testes of 
individual animals extracted on RNeasy 5 
columns (QIAGEN, Valencia, CA). RNA was 
quantified using a NanoDrop ND-1000 
(NanoDrop Wilmington, DE) and RNA quality 
was checked using the Agilent bioanalyzer 
2100 (Agilent, Santa Clara, CA). Samples of  10 
total RNA (8µg) from individual animals were 
reverse transcribed and then in vitro transcribed 
and hybridised to mouse MOE430A arrays 
(Affymetrix, Santa Clara, CA) (n = 3 or 4 for 
each group) according to the Genechip 15 
expression technical manual (Affymetrix) as 
previously reported (23). All the experiments 
were designed and information compiled in 
compliance with MIAME guide lines. Gene 
transcript levels were determined from data 20 
image files using algorithms in Gene Chip 
Operating Software (GCOS1.2, Affymetrix).  
The array data were generated in two 
batches. In the first experiment control, 12h 
and 72h FSH groups were extracted and 25 
hybridised to the arrays and in a subsequent 
experiment control and 24h FSH groups were 
processed in the same way. Each treatment 
group was analysed against its own control. 
Differentially expressed genes were identified 30 
using the Welch t-test, parametric test, variance 
not assumed equal, p<0.05. To generate data 
for cluster analysis the control groups were 
pooled. Clustering was carried out using a 
heuristic iterative two-step algorithm (24) 35 
(www.esat.kuleuven.ac.be/
dna/BioI/Software.html). Further analysis of 
potential interactions between significantly 
altered  transcripts was partly carried out using   
Ingenuity Pathways Analysis  40 
(www.ingenuity.com). 
The data discussed in this publication 
have been deposited in NCBIs Gene 
Expression Omnibus (GEO, 
http://www.ncbi.nlm.nih.gov/geo/) and are 45 
accessible through GEO Series accession 
GSE8924. 
 
Real-time PCR  
Total RNA was extracted from individual 50 
testes of control or FSH-treated hpg mice using 
Trizol (Life technologies, Paisley, UK) and 
residual genomic DNA was removed by 
DNAse treatment (DNA-free, Ambion Inc 
supplied by AMS Biotechnology, Abingdon, 55 
UK). RNA (1µg) was reverse transcribed using 
random hexamers (Ambion) and Moloney 
murine leukaemia virus reverse transcriptase 
(Life Technologies) as previously described 
(25).  60 
Quanitative real-time PCR was used to 
confirm changes in selected mRNA transcripts 
identified from the microarray analysis or to 
examine other transcripts of potential interest. 
The real-time PCR used either the Taqman 65 
(Inha, Inhba, Inhbb and Hdc) or the SYBR 
green (all other transcripts) method  in a 96-
well plate format. For Taqman, Universal 
Taqman master mix and optimised primer and 
probe sets were purchased from Applied 70 
Biosystems (Warrington, UK) and used 
according to the manufacturers 
recommendations in a 25µl volume. For SYBR 
green, each reaction contained 5µl 2 x SYBR 
mastermix (Stratagene, Amsterdam, 75 
Netherlands), primer (100nM) and template in 
a total volume of 10µl.  The thermal profile 
used for amplification was  95oC for 8min 
followed by 40 cycles of 95oC for 25 secs, 
63oC for 25 sec and 72oC for 30 sec. At the end 80 
of the amplification phase a melting curve 
analysis was carried out on the products 
formed. All primers were designed by Primer 
Express 2.0 (Applied Biosystems, Warrington, 
UK) using parameters previously described 85 
(26). No-RT controls for each sample were 
screened to check for the presence of residual 
genomic DNA.  The primers and probes used 
for real-time SYBR PCR are shown in 
Supplementary Table 1. Different animals were 90 
used to provide RNA for real-time PCR and 
microarray studies. 
 
Hormone assay 
In a separate study adult hpg mice were treated 95 
with rFSH as above and intratesticular levels of 
testosterone measured by radioimmunoassay 
following ethanol extraction as previously 
described (27). The limit of detection of the 
assay was 25 fmol/testis. 100 
 
Statistical analysis 
With the exception of the array studies 
described above, the effects of FSH treatment 
were analysed initially by single-factor 105 
ANOVA followed by post hoc analysis using 
Fisher’s test. 
  
Results 
Testicular weight and histology after rFSH 110 
treatment. 
There was a significant increase in testis 
weight within 12h of the start of FSH treatment 
 5 
and weight continued to increase up to 24h (Fig 
1A). This weight increase was accompanied by 
an apparent increase in tubular diameter with 
clear formation of a tubular lumen (Fig 1B). 
On the semi-thin light micrographs there was 5 
also an apparent increase in vacuolation of the 
Sertoli cell cytoplasm by 24 hours which 
became more marked by 72h (Fig 1B).  This 
was confirmed on electron micrographs with 
several small vacuoles apparent within the 10 
cytoplasm at 24h and larger vacuoles present at 
72 hours (Fig 1C).  There was no clear 
advancement of spermatogenesis within the 
timescale of the experiment. 
 15 
Hormone levels 
Intratesticular testosterone levels were 
undetectable in control hpg mice 
(<25fmol/testis, n=8) and increased to low but  
consistently detectable levels 24h after the start 20 
of treatment with FSH (65.0 ± 12.4 fmol/testis, 
n=4) and remained detectable up to 72h (76.2 ± 
45.0 fmol/testis, n=4)  .  
 
Microarray data 25 
Analysis of the array data showed that there 
were 182, 164, and 203 transcripts significantly 
(>2 fold) increased in the hpg testis  12, 24 and 
72h after the start of FSH treatment  and 162, 
411 and 215 significantly decreased at the 30 
same times.  Cluster analysis showed that there 
were 5 clusters containing more than 70% of 
the significantly altered transcripts and the 
three predominant clusters are shown in 
Supplementary Fig 1.  35 
Transcripts with the highest fold-
changes in expression at each time during 
treatment  are listed in Table 1 and the 
complete list of significantly altered transcripts 
is shown in Supplementary Table 2.  At 12h 40 
after the start of FSH treatment there was a 
clear increase in the levels of a number of  
transcripts known to be expressed in the Sertoli 
cells (eg Fabp5, Lgals1, Tesc, Scara5) (28-31) 
and, perhaps surprisingly, in the Leydig cells 45 
(eg Ren1, Cyp17a1, Akr1b7, Star, Ldlr, Nr4a1) 
(32-35) (Table 1). Other transcripts listed in 
Table 1 do not have a known site of expression 
in the testis although 6 of these transcripts are 
known to be secreted from the cell (Dmkn, 50 
Wif1, Col4a1, Pappa, Svs5, Dkk3) and may be 
involved in the paracrine regulation induced by 
FSH. By 24h after the start of FSH treatment, 
androgen-dependent Sertoli cell transcripts 
appeared in the list of up-regulated transcripts 55 
(eg Rhox5, Drd4, Spinlw1, Tubb3 and Tsx) (36-
39) and this trend became more marked by 
72h. Surprisingly, very few germ cell genes 
appear on the lists of significantly regulated 
transcripts. Only Hdc (increased 4.0 and 5.9- 60 
fold at 24 and 72h respectively) (40) and  
1700021K02Rik (Spatial) (increased 3.1-fold at 
72 h) (41) are significantly altered by FSH 
(Table 1 and Supplementary Table 2). 
 65 
Real-time PCR 
Leydig cell genes  
To confirm results from the array studies real-
time PCR was used to measure the effect of 
FSH treatment on testicular expression of 70 
selected transcripts which are known to be 
expressed exclusively in the Leydig cells (42). 
Eight mRNA species were tested which had 
shown an increase in transcript levels on the 
arrays after FSH (Star, Cyp17a1, Hsd17b3, 75 
Akr1b7, Lhr, Cyp11a1, Insl3 and Ren) (Fig 
2A). Results from the real-time PCR studies 
confirmed that seven of these transcripts are 
regulated by FSH in the hpg testis although no 
change in Lhr was seen. Two other Leydig cell 80 
mRNA species (Hsd3b6 and Sult1e1) which 
had not shown any response to FSH on the 
arrays were also tested by real-time PCR (Fig 
2A). Levels of Hsd3b6 did not show a response 
to FSH but there was a significant, if variable, 85 
increase in Sult1e1 after 72h.  
 
Androgen-dependent genes 
The array studies showed clearly that a number 
of androgen-dependent Sertoli cell transcripts 90 
were altered after FSH treatment. Real-time 
PCR was used to confirm changes in selected 
transcripts (Rhox5, Tsx, Drd4, Spinlw1 (eppin) 
and Igfbp3) shown previously to be androgen-
regulated (36;38;39) (Fig 2B). In agreement 95 
with results from the array studies 4 transcripts 
(Rhox5, Tsx, Drd4 and Spinlw1) showed 
increased expression 24-72h after FSH 
treatment while 1 transcript (Igfbp3) showed a 
significant decrease in expression (Fig 2B). 100 
 
Sertoli cell genes 
In addition to androgen-dependent Sertoli cell 
genes described above, 14 other known Sertoli 
cell transcripts were measured by real-time 105 
PCR following FSH treatment of adult hpg 
mice (Fig 3). Of these Sertoli cell transcripts 5 
had shown significantly increased expression 
on the arrays (Tesc, Lgals1, Aqp5, Dhh and 
Shbg), 6 had not shown any significant change 110 
(Trf, Wt1, Amh, Spata2, Tjp1 and Gdnf), 2 had 
shown a significant decrease (Fshr and Rgs11) 
after FSH treatment and one transcript 
(Defb19) was not on the array. Results from 
 6 
real-time studies confirmed increased levels of 
transcript for 4 out of the 5  mRNA species 
identified on the array (the exception was 
Shbg) and for the one transcript (Defb19) not 
on the array (Fig 3A). Both transcripts 5 
decreased on the arrays after FSH treatment 
also showed a significant decrease  by real-time 
PCR (Fig 3A). Interestingly, however, the real-
time PCR data showed there was a significant 
increase in levels of 3 of the 6 transcripts 10 
which were not significantly changed on the 
arrays (Trf, Wt1, and Amh) (Fig 3A).  Two of 
these transcripts (Trf and Amh) had shown a 
greater than 2-fold increase on the arrays but 
had not reached significance. 15 
 The inhibin subunits are expressed in a 
number of cell types in the testis (43) although 
it might be expected that initial responsiveness 
to FSH would be predominantly localised in 
the Sertoli cells. On the arrays both Inha and 20 
Inhbb were significantly increased by FSH 
(Table 1 and Supplementary Table 2) while 
there was no effect on Inhba. Results from the 
real-time PCR studies reflected the same 
pattern of results (Fig 3B). 25 
   
Germ cell genes 
Failure of FSH treatment to have a marked 
effect on germ cell transcripts in the hpg testis 
was tested using real-time PCR. Expression of 30 
8 germ cell transcripts known to be expressed 
predominantly in spermatogonia (Stra8, Oct4, 
Dkkl1 and Spo11) spermatocytes (Mybl1) or 
spermatids (1700021K02Rik (spatial), Hdc and 
Tp1) was measured following FSH treatment 35 
(Fig 4). Expression levels of Stra8, Spo11, 
Mybl1 and Tp1 were unaffected by treatment 
but there was a transient increase in Oct4 at 
12h  while Dkkl1 showed a variable but 
significant increase at 72h. Expression of Hdc 40 
and  1700021K02Rik (shown previously to be 
increased on the array) was increased at all 
times after treatment.  
 
Other transcripts 45 
Results from the array studies identified a 
number of transcripts regulated by FSH but 
without known function and/or known 
expression pattern in the testis. Levels of 6 of 
these transcripts (Wif1, Dmkn, Dkk3, Pappa, 50 
Wnt4 and Tfrc) were measured in hpg testes 
after FSH treatment (Fig 5). In all cases FSH 
caused a significant increase in transcript levels 
confirming the results of the array study.  
   55 
 
 
Pathway analysis 
Analysis of significantly regulated transcripts 
(>1.5 fold) showed that there were alterations 60 
in cell cycle and cell proliferation pathways at 
all times (Supplementary Fig 2). At 12h after 
the first injection up-regulation of the pathway 
components predominated but as treatment 
continued there was a shift to down-regulation, 65 
particularly at 72h. Analysis of canonical 
pathways showed that components of the 
cholesterol biosynthetic pathway were 
significantly increased at 12h but not at other 
times (Supplementary Table 3A) and that there 70 
was a general decline in transcripts encoding 
factors involved in formation and regulation of 
tight junctions (Supplementary Table 3B).  
 
 75 
Discussion 
 
FSH is essential for optimum fertility in the 
adult male but uncertain remains about how it 
acts to regulate Sertoli cell activity and 80 
spermatogenesis. The hpg mouse is an 
excellent model system with which to test the 
effects of FSH since the Sertoli cells have not 
been exposed to the hormone but express 
FSHR and are sensitive to FSH action. This 85 
study  is an extension of earlier work by 
Sadate-Ngatchou et al (21) using a longer 
treatment period, different array chips with a 
larger characterised gene set (14,000 vs 6000 
characterised genes) and with a larger animal 90 
cohort. Together, the two studies complement 
each other and serve to identify transcripts 
regulated by FSH over the short and medium 
term. The studies are not directly comparable, 
however, because of differences in time-course 95 
and treatment regime but the transcript lists can 
be compared with some caution at 12h. At this 
time the main difference is that animals used 
for this study will have been treated twice with 
FSH while those used by Sadate-Ngatchou et 100 
al (21) have been injected once. This 
comparison shows that at 12h after the start of 
FSH treatment there are 44 transcripts in 
common between the studies, 25 upregulated 
and 19 downregulated (Supplementary Table 105 
3).  
In this study, the total number of 
transcripts altered at each time point did not 
vary markedly across the treatment period but 
only 39 transcripts were upregulated more than 110 
2 fold at all times (Supplementary Table 4A) 
indicating that there was a changing pattern of 
expression as the exposure to FSH was 
maintained. There were also 63 transcripts 
 7 
downregulated more than 2 fold at all times 
(Supplementary Table 4B) suggesting that the 
inhibitory effects of FSH are more consistent. 
Results from the arrays and from real-time 
PCR showed that FSH treatment caused a 5 
general increase in many transcripts encoding 
known Sertoli cell specific products such as 
Tesc, Lgals1, Fabp5 and Aqp5 (28-30) 
although some transcripts (eg Shbg, Tjp1 
(44;45)) were unaffected while others were 10 
decreased (see below) indicating that the effect 
of FSH was not simply to increase the overall 
activity of the cells.   
Among the transcripts which showed 
decreased levels in response to FSH were a 15 
number encoding tight junction components. 
This is consistent with  a recent study which 
reported that gonadotrophins reduce transcript 
levels of Sertoli cell barrier components but 
that FSH may act at the level of protein 20 
organisation to induce barrier functionality 
(46). Other transcripts which showed a 
significant decrease in levels after FSH 
treatment included Fshr  and Rgs11. It is well 
established that FSH will cause downregulation 25 
of its receptor  by decreasing transcript levels 
(47;48) and a reduction in Fshr is to be 
expected. RGS11, in contrast,  belongs to the 
Regulator of G protein Signalling family which 
are GTPase-activating proteins that act to 30 
inhibit signal transduction and thus play a role 
in desensitisation (49). The role of  RGSs in 
normal hormonal signalling is not well 
established but the declining levels of Rgs11 
after FSH treatment may act to enhance signal 35 
transduction despite a reduction in receptor 
levels.  
 In addition to changes in Sertoli cell 
transcripts induced by FSH it was clear from 
the rise in testicular androgen and the array and 40 
real-time PCR data that FSH was also acting to 
induce Leydig cell function. This effect was 
marked and rapid with a Leydig cell transcript 
(Ren1) showing the greatest fold change at 12h 
(32). Results from the arrays and real-time 45 
PCR show that all components of the androgen 
biosynthetic pathway were induced at 12h apart 
from Hsd3b6. Since Hsd3b1 is already highly 
expressed in the adult hpg testis (50) lack of 
HSD3B6 is unlikely to affect the steroidogenic 50 
potential of the cells. In addition to the 
steroidogenic enzymes, pathway analysis 
showed that most components of the 
cholesterol biosynthetic pathway were induced 
12h after FSH treatment while Ldlr levels are 55 
increased. This shows that FSH is acting to 
increase the capacity of the Leydig cells to 
produce and sequester cholesterol and to 
convert cholesterol to androgen. The hpg 
mouse testis is likely to contain both adult and 60 
fetal-type Leydig cells (50) and Hsd3b6 is a 
marker of adult Leydig cell differentiation (51). 
This  might imply that FSH is acting to induce 
activity in the fetal Leydig cell population but 
Sult1e1 is also a marker of adult Leydig cells 65 
(52) and is increased 72h after FSH suggesting 
that the effects of FSH are probably being 
mediated through the adult Leydig cells. 
In the testis, receptors for FSH are only 
found in the Sertoli cells (53) and the effects of 70 
FSH must be mediated by a factor or factors 
released by the Sertoli cells which act on the 
Leydig cells. In the short-term the effects of 
FSH on Leydig cell function in the hpg appear 
to be more marked than effects of hCG (50) 75 
and the effects are also very rapid since Sadate-
Ngatchou et al (21) saw a marked increase in 
Cyp17a1 after only 4h of FSH treatment. FSH 
appears, therefore, to be able to induce a 
powerful and rapid response in Leydig cells 80 
presumably through stimulation of release of 
potent trophic factors by the Sertoli cells. The 
presence of such factors has been postulated for 
a number of years since early studies on 
perfused testes or hypophysectomised animals 85 
treated with FSH (54-56). One report has 
suggested that the active factors are TIMP1 and  
Procathepsin L (57) but this has not been 
confirmed and we saw no evidence of changes 
in these factors in our study. Following FSH 90 
treatment, our array data showed that there was 
an increase in Igf1 levels and IGF1 has been 
suggested to play a role in Leydig cell 
differentiation (58).  Interestingly, there was a 
marked decline in Igfbp3 and an increase in 95 
Pappa levels after FSH treatment. Increased 
Pappa  would be expected to increase the 
bioavailabitity and activity  of IGF1 (59) 
although the effect of altered Igfbp3 may be 
more complex (60). The time course of 100 
changes in expression of Igf1 levels does not 
appear to fit well with a role in the stimulation 
of Leydig cell function after FSH treatment 
although it is possible that early changes in 
Pappa and Igfbp3 may alter early IGF1 105 
bioavailability. Other secreted molecules 
showing a marked increase in transcript levels 
after FSH include Wif1, Dkk3 and Dmkn. Both 
WIF1 and DKK3 act to regulate WNT 
signalling and the WNT/CTNNB1 pathway is 110 
critical for normal Sertoli cell development 
(61) although its function in the Leydig cell 
remains uncertain. 
 8 
Following the increase in Leydig cell 
activity after FSH treatment there was a 
significant change in the levels of  known 
androgen-dependent Sertoli cell-specific 
transcripts starting, in most cases, 24h after the 5 
first FSH injection.  It is possible that changes 
in these transcripts are due to direct effects of 
FSH treatment but the known androgen-
dependence of the transcripts makes it more 
likely that changes are related to increased 10 
Leydig cell androgen production induced by 
FSH. The  rise in intratesticular androgen after 
FSH treatment was significant but levels 
remained very low, probably because FSH 
stimulates synthesis of the components of the 15 
steroidogenic pathway without being able to 
stimulate the pathway itself. The apparent 
effect of these low levels of androgen on 
Sertoli cell transcript levels suggests that the 
Sertoli cells are extremely sensitive to 20 
androgen stimulation.  
 Treatment of hpg mice with FSH 
increased vacuolation in the Sertoli cells and  
induced formation of a lumen within the 
seminiferous tubules but had little apparent 25 
effect on germ cell morphology or progression 
up to 72h.  Changes in the Sertoli cell and 
tubule diameter correlate with a marked rise in 
Aqp5 at 12hours suggesting that increased 
water movement across the Sertoli cell 30 
membrane may contribute to increased tubular 
diameter and testis weight.  The failure of FSH 
to have a marked effect on spermatogenesis 
within the time-course of the experiment was 
reflected in a relative lack of effect on germ 35 
cell transcripts on the arrays. Subsequent real-
time PCR studies of a small number of known 
germ cell genes largely confirmed the array 
data but showed a significant increase in Oct4 
and Dkkl1 not seen on the arrays. OCT4 has 40 
been shown to be necessary for primordial 
germ cell survival (62) and the increase in 
response to FSH, albeit small, may facilitate an 
increase in spermatogonial number within the 
testis. Both Hdc and Spatial are associated with 45 
round spermatids and the later stages of 
spermatogenesis (40;41) suggesting that the 
expression detected in this study must either be 
associated with earlier stages of 
spermatogenesis or with a different, somatic 50 
cell type.    It has been shown previously that 
more prolonged treatment of hpg mice with 
FSH will stimulate an increase in germ cell 
number and development (5;63;64) but results 
from this study suggest that FSH has little 55 
stimulatory effect in the short term. In the 
longer term, the stimulatory effect of FSH on 
the Leydig cells makes interpretation of the 
FSH effects on the germ cells difficult because 
of the known stimulatory effect of testosterone 60 
on germ cell development in the hpg mouse 
(27;65).  
 In this study,  FSH treatment of hpg 
mice for up to 72h induced significant changes 
in Sertoli cell transcript levels and led to 65 
indirect stimulation of Leydig cell function. 
The changes in Leydig cell activity probably 
induced further changes in androgen-dependent 
Sertoli cell transcripts.  While FSH is known to 
be required for optimal germ cell development 70 
(12;15) it had little effect on germ cell 
transcript levels up to 72h suggesting that 
longer-term action of FSH is required to affect 
spermatogenesis.   
 75 
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Figure legends 
Figure 1 Effect of FSH on testis weight and morphology in hpg mice.  A) Testis weights of adult hpg 
mice treated every 12h with FSH. B) Semi thin sections of  testes from  control adult hpg and from  
mice treated with FSH for 12, 24 and 72 hours. Note the appearance of vacuoles within the cytoplasm of 
the Sertoli cell at 24 and 72 hours post treatment. C) Electron micrographs at 24h and 72h, arrows 5 
indicate the progression from multiple small vacuoles to fewer large vacuoles. 
 
Figure 2  Real-time PCR measurements of mRNA transcript levels in testes from adult hpg mice treated 
for 0 (control), 12, 24, or 72h with FSH. Data show results from Leydig cell-specific  transcripts (A) 
and from Sertoli cell-specific, androgen-dependent transcripts (B). The mean ± sem of 3 or 4 animals 10 
per group is shown. Groups with different letter superscripts are significantly different.  
 
Figure 3 Real-time PCR measurements of Sertoli cell-specific mRNA transcript levels in testes from 
adult hpg mice treated for 0 (control), 12, 24, or 72h with FSH. Results show the mean ± sem of 3 or 4 
animals per group. Groups with different letter superscripts are significantly different, where no 15 
superscripts are shown there was no difference between groups. 
 
Figure 4 Real-time PCR measurements of germ cell-specific mRNA transcript levels in testes from 
adult hpg mice treated for 0 (control), 12, 24, or 72h with FSH. Results show the mean ± sem of 3 or 4 
animals per group. Groups with different letter superscripts are significantly different, where no 20 
superscripts are shown there was no difference between groups. 
 
Figure 5 Real-time PCR measurements of  transcript levels mRNA species with unknown testicular 
origin. Levels were measured in testes from adult hpg mice treated for 0 (control), 12, 24, or 72h with 
FSH. Results show the mean ± sem of 3 or 4 animals per group. Groups with different letter superscripts 25 
are significantly different. 
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Table 1 Effects of FSH treatment on testicular transcript levels – highest-regulated transcripts 
from microarray studies  
 
Transcripts up-regulated 12h after start of treatment Transcripts down-regulated 12h after start of treatment 
Fold Gene   Fold Gene   
change symbol Gene Title change symbol Gene Title 
20.7 Ren1 renin 1 structural  7.27 Myh8 myosin, heavy polypeptide 8 
18.2 Dmkn dermokine 6.65 Rin2 Ras and Rab interactor 2  
13.3 Aqp5 aquaporin 5  5.03 Pdgfc platelet-derived growth factor C  
12.1 Wif1 Wnt inhibitory factor 1 4.55  Transcribed locus* 
11.0 Fabp5 fatty acid binding protein 5, epidermal 4.53 Bcan brevican 
6.6 Tubb3 tubulin, beta 3 4.46 Rgs11 regulator of G-protein signaling 11 
6.5 Cyp17a1 cytochrome P450, family 17a 1 4.45 Tmem37 transmembrane protein 37 
6.3 Akr1b7 aldo-keto reductase family 1 B7 4.43 Fhod3 formin homology 2 domain containing 3 
6.0 Lgals1 lectin, galactose binding, soluble 1 4.38 Derl3 Der1-like domain family, member 3 
5.9 Col4a1 procollagen, type IV, alpha 1 4.01 Ddit4l DNA-damage-inducible transcript 4-like 
5.7 Pappa pregnancy-associated plasma protein A 3.98 BC013672 cDNA sequence BC013672 
5.2 Star steroidogenic acute regulatory protein 3.97 Scin scinderin 
4.6 Ldlr low density lipoprotein receptor 3.96 Ddit4l DNA-damage-inducible transcript 4-like 
4.6 Tesc tescalcin  3.89 Cabc1 chaperone, ABC1 complex like  
4.6 Rps6ka2 ribosomal protein S6 kinase 2 3.86 Krt20 keratin 20 
4.6 Scara5 scavenger receptor class A 5  3.74 Tmem140 transmembrane protein 140 
4.4 Hgsnat Heparan  N-acetyltransferase 3.71 Dbp D site albumin promoter binding protein 
4.4 Hs3st1 heparan sulfate  3-O-sulfotransferase 1 3.71 Rnasel ribonuclease L 
4.2 Syne1 synaptic nuclear envelope 1 3.70 Spsb1 splA receptor domain and SOCS box  1 
4.1 Slc38a5 solute carrier family 38, member 5 3.67 Tnni3 troponin I, cardiac 
4.0 Gpd1 glycerol-3-phosphate dehydrogenase 1  3.65 Cdo1 cysteine dioxygenase 1, cytosolic 
3.9 Dos downstream of Stk11 3.57 Stard8 START domain containing 8 
3.8 Svs5 seminal vesicle secretory protein 5 3.55 Slc40a1 solute carrier family 40, member 1 
3.8 Bhmt betaine-homocysteine methyltransferase 3.52 Hdac5 histone deacetylase 5 
3.7 D9Ertd280e Chr 9, ERATO Doi 280 3.32 Dbp D site albumin promoter binding protein 
3.7 Tnfrsf12a tumor necrosis factor receptor 12a 3.23 Chdh choline dehydrogenase 
3.7 1200016E24Rik  RIKEN cDNA 1200016E24  3.23 8030411F24Rik RIKEN cDNA 8030411F24 gene 
3.7 Nr4a1 nuclear receptor subfamily 4, group A1 3.23 Per3 period homolog 3 (Drosophila) 
3.6 Dkk3 dickkopf homolog 3  3.22 Ctnna2 catenin, alpha 2 
3.6 Cyp51 cytochrome P450, family 51 3.19 Trim47 tripartite motif protein 47 
      
Transcripts up-regulated 24h after start of treatment Transcripts down-regulated 24h after start of treatment 
Fold  Gene   Fold  Gene   
change symbol Gene title change Smbol Gene title 
28.8 Lin7c lin-7 homolog C (C. elegans) 9.9 Ddit4l DNA-damage-inducible transcript 4-like 
18.0 Cyp17a1 cytochrome P450, family 17a1 9.9 Rin2 Ras and Rab interactor 2  
13.6 Cyp11a1 cytochrome P450, family 11a1 9.1 Slc40a1 solute carrier family 40, member 1 
11.0 Fabp5 fatty acid binding protein 5, epidermal  8.0 Rgs11 regulator of G-protein signaling 11 
10.1 Rhox5 reproductive homeobox 5 7.6 Igfbp3 insulin-like growth factor binding protein 3 
9.4 Star steroidogenic acute regulatory protein 7.4 Myh6 myosin, heavy polypeptide 6 alpha 
8.7 Slc38a5 solute carrier family 38, member 5 7.2 Apbb2 amyloidprecursor protein-binding B2 
7.9 Aqp5  aquaporin 5 6.7 Rassf5 Ras association domain family 5 
7.4 Tubb3 tubulin, beta 3 6.3 Tmem37 transmembrane protein 37 
7.0 Drd4 dopamine receptor 4 6.3 Chdh choline dehydrogenase 
6.3 Tesc tescalcin  6.2 Itga9 integrin alpha 9 
5.5 Lgals1 lectin, galactose binding, soluble 1 6.2 Thbd thrombomodulin 
5.0 Spinlw1 eppin 5.9 Fcgr2b Fc receptor, IgG, low affinity IIb 
4.6 Osr1 odd-skipped related 1  5.8 Trim47 tripartite motif protein 47 
4.5 Fads2 fatty acid desaturase 2 5.7 Spsb1 splA receptor domain and SOCS box  1 
4.2 Pappa pregnancy-associated plasma protein A 5.6 Ddit4l DNA-damage-inducible transcript 4-like 
4.2 Scara5 scavenger receptor class A5  5.5 Vnn1 vanin 1 
4.2 Pscdbp pleckstrin homology binding protein 5.5 Fcgr2b Fc receptor, IgG, low affinity IIb 
4.1 Plac8 placenta-specific 8 5.4 Ptprd protein tyrosine phosphatase, receptor D 
4.0 Gpt2 glutamic pyruvate transaminase 2 5.4 Nkx3-1 NK-3 transcription factor, locus 1  
4.0 Rps6ka2 ribosomal protein S6 kinase 2 5.3 Fcgr2b Fc receptor, IgG, low affinity IIb 
4.0 Gpd1 glycerol-3-phosphate dehydrogenase 1 5.1 Ctgf connective tissue growth factor 
4.0 Hdc histidine decarboxylase 5.0 H19 H19 fetal liver mRNA 
3.8 Igf1 insulin-like growth factor 1 5.0 Pdgfc platelet-derived growth factor C 
3.7 Fah fumarylacetoacetate hydrolase 4.9 Hsd17b11 hydroxysteroid (17β) dehydrogenase 11 
3.7 Mpzl2 myelin protein zero-like 2 4.9 Cabc1 chaperone, ABC1complex like 
3.6 Insl3  insulin-like 3  4.9 9630031F12Rik RIKEN cDNA 9630031F12 gene 
3.4 Wif1 Wnt inhibitory factor 1 4.8 Ptch1 patched homolog 1 
3.3 Inha inhibin alpha 4.7 Smoc2 SPARC related modular calcium binding 2 
3.2 Col18a1 procollagen, type XVIII, alpha 1 4.7 Fhod3 formin homology 2 domain containing 3 
      
Transcripts up-regulated 72h after start of treatment Transcripts down-regulated 72h after start of treatment 
Fold  Gene  Fold Gene   
change symbol Gene title change symbol Gene title 
35.0 Drd4 dopamine receptor 4 13.4 Igfbp3 insulin-like growth factor binding protein 3 
21.1 Slc38a5 solute carrier family 38a5 8.2 Rgs11 regulator of G-protein signaling 11 
14.9 Rhox5 reproductive homeobox 5 6.6 Rin2 Ras and Rab interactor 2  
13.9 Fabp5 fatty acid binding protein 5, epidermal 6.5 Clca1  chloride channel calcium activated 1  
8.4 Spinlw1 eppin 6.0 Slc40a1 solute carrier family 40 1 
7.6 Klk1b24 kallikrein 1-related peptidase b24 5.6 Spsb1 splA receptor domain and SOCS box  1 
6.6 Tubb3 tubulin, beta 3 4.9 Ifitm1 interferon induced transmembrane 1 
5.9 Hdc histidine decarboxylase 4.7 Myh8 myosin, heavy polypeptide 8 
5.5 Fah fumarylacetoacetate hydrolase 4.6 Fhod3 formin homology 2 domain containing 3 
5.5 Tsx testis specific X-linked gene 4.4 Bcan brevican 
5.4 Zcchc18 zinc finger, CCHC domain 18 4.4 Tmem140 transmembrane protein 140 
4.6 Sct secretin 4.4 BC013672 cDNA sequence BC013672 
4.6 Gpd1 glycerol-3-phosphate dehydrogenase 1 4.3 Tmem37 transmembrane protein 37 
4.5 Myh1 myosin, heavy polypeptide 1 4.0 Erbb3 v-erb-b2  homolog 3 
4.5 Fabp4 fatty acid binding protein 4, adipocyte 3.9 Dst dystonin 
4.5 St8sia2 ST8 sialyltransferase 2 3.9 Xist inactive X specific transcripts 
4.5 Tgfb1 transforming growth factor, beta 1 3.8 Arhgdig Rho GDP dissociation inhibitor gamma 
4.3 Pscdbp pleckstrin homology binding protein 3.7 Edn1 endothelin 1 
4.2 Igf1 insulin-like growth factor 1 3.7 6330403K07Rik RIKEN cDNA 6330403K07 gene 
4.1 Scara5 scavenger receptor class A, member 5  3.7 Jun Jun oncogene 
4.1 Sept6 septin 6 3.6 Pla2g5 phospholipase A2, group V 
4.0 D17H6S56E-5 Chr 17, human D6S56E 5 3.6 Apbb2 amyloid beta precursor protein-binding B2 
4.0 Pappa pregnancy-associated plasma protein A 3.6 H19 H19 fetal liver mRNA 
4.0 Klk1 kallikrein 1 3.6 Hspb1 heat shock protein 1 
3.9 Dmkn dermokine 3.6 Fcgr2b Fc receptor, IgG, low affinity IIb 
3.8 Tpd52l1 tumor protein D52-like 1 3.5  Transcribed locus** 
3.8 Inha inhibin alpha 3.5 Adi1 acireductone dioxygenase 1 
3.8 Slc25a5 solute carrier family 25, member 5  3.4 H2-T23  histocompatibility 2, T region locus 23  
3.7 Car3 carbonic anhydrase 3 3.4 Scin scinderin 
3.7 Pde4b phosphodiesterase 4B, cAMP specific 3.3 Rnasel ribonuclease L  
      
    * Net affy number 1454967_at 
    ** Net afy number 1436092_at 
 
